Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
The KILR cytotoxicity assay platform provides a robust and sensitive solution to measure the killing of antigen-expressing target cells in co-culture with effector cells. The platform allows for the quantification of direct cell death through multiple mechanism of actions (MOAs), including ADCC (antibody-dependent cell-mediated cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), CDC (complement-dependent cytotoxicity, and T-cell redirection.
Eurofins DiscoverX®’s KILR bioassays are plate-based, homogeneous ready-to-use (RTU) cell-based assay kits that include all necessary reagents to run the assay. These physiologically relevant, robust bioassays are fit-for-purpose for use in screening and characterization applications to potency testing in quality control (QC) lot-release programs. The KILR RTU bioassays demonstrate extensive lot-to-lot consistency in assay performance and help ensure long-term assay reproducibility with high signal-to-background ratios, key factors in potency lot-release testing programs. The KILR platform provides the flexibility to use your effector cells of choice. Additional custom assay development capabilities are available to generate optimized bioassays with your target cell model of interest and for relevant data generation.
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Bioassay Kit Name | Cancer Cell Type | Target | Assay Measures | Drug Name |
---|---|---|---|---|
KILR ADCC Bioassay Kit (NCI-N87 cell types) |
- | HER2 | ADCC | |
KILR ADCC Bioassay Kits (Daudi and Raji cell types) |
Burkitt’s lymphoma | CD19, CD20, CD38 | ADCC | Rituximab |
KILR ADCP Bioassay Kits (Daudi and Raji cell types) |
Burkitt’s lymphoma | CD19; CD20; CD38 | ADCP | Rituximab |